Canada Life
AIMT

Canada Life’s Aimmune Therapeutics AIMT Stock Holding History

Canada Life’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,879
Closed -$99K – 2695
2020
Q3 		$99K Hold
2,879
– – ﹤0.01% 2041
2020
Q2 		$48K Hold
2,879
– – ﹤0.01% 2232
2020
Q1 		$42K Hold
2,879
– – ﹤0.01% 2184
2019
Q4 		$96K Buy
+2,879
New +$80.5K ﹤0.01% 2080
2019
Q3 		– Sell
-5,426
Closed -$113K – 2632
2019
Q2 		$113K Hold
5,426
– – ﹤0.01% 2176
2019
Q1 		$121K Buy
5,426
+2,111
+64% +$49.7K ﹤0.01% 2013
2018
Q4 		$76K Hold
3,315
– – ﹤0.01% 2239
2018
Q3 		$91K Hold
3,315
– – ﹤0.01% 2224
2018
Q2 		$89K Hold
3,315
– – ﹤0.01% 2233
2018
Q1 		$106K Hold
3,315
– – ﹤0.01% 2144
2017
Q4 		$125K Hold
3,315
– – ﹤0.01% 2111
2017
Q3 		$81K Hold
3,315
– – ﹤0.01% 2209
2017
Q2 		$68K Hold
3,315
– – ﹤0.01% 2229
2017
Q1 		$72K Hold
3,315
– – ﹤0.01% 2208
2016
Q4 		$68K Buy
+3,315
New +$67.8K ﹤0.01% 2236

Canada Life's AIMT Position: Q4 2020 in Review

Canada Life sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 2,879 shares — an estimated $99K sold.

Canada Life first reported a position in AIMT in Q4 2016 and held it in 15 quarters. The position peaked at $125K in Q4 2017. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Canada Life reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Canada Life sold 2,879 Aimmune Therapeutics shares in Q4 2020, an estimated $99K.
  • Canada Life first reported a position in Aimmune Therapeutics in Q4 2016 and held it in 15 quarters.
  • Canada Life's Aimmune Therapeutics position peaked at $125K in Q4 2017.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Canada Life's 13F filing for Q4 2020, filed 16 Feb 2021.